ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) TSE: EPI's share price crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.68 and traded as low as $1.55. ESSA Pharma shares last traded at $1.55, with a volume of 82,165 shares.
ESSA Pharma Price Performance
The company has a market cap of $69.25 million, a PE ratio of -2.26 and a beta of 1.59. The business has a fifty day simple moving average of $1.67 and a two-hundred day simple moving average of $2.84.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.01). On average, equities research analysts predict that ESSA Pharma Inc. will post -0.42 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC purchased a new stake in ESSA Pharma in the fourth quarter valued at about $26,000. Two Sigma Securities LLC acquired a new position in ESSA Pharma during the fourth quarter valued at $29,000. GTS Securities LLC purchased a new stake in ESSA Pharma in the fourth quarter valued at $30,000. FNY Investment Advisers LLC acquired a new stake in ESSA Pharma during the 4th quarter worth about $44,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of ESSA Pharma during the 4th quarter valued at about $47,000. 75.12% of the stock is currently owned by hedge funds and other institutional investors.
ESSA Pharma Company Profile
(
Get Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Featured Stories
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
